{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T02:11:56Z","timestamp":1780625516348,"version":"3.54.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,12,11]],"date-time":"2018-12-11T00:00:00Z","timestamp":1544486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Boehringer Ingelheim RCV GmbH","award":["79115"],"award-info":[{"award-number":["79115"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Med"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s00109-018-1725-7","type":"journal-article","created":{"date-parts":[[2018,12,11]],"date-time":"2018-12-11T20:02:48Z","timestamp":1544558568000},"page":"231-242","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma"],"prefix":"10.1007","volume":"97","author":[{"given":"Viktoria","family":"Laszlo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna","family":"Valko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Ozsvar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ildiko","family":"Kovacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamas","family":"Garay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mir Alireza","family":"Hoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Klikovits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Stockhammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Aigner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Gr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Klepetko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Grusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jozsef","family":"Tovari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene C.","family":"Waizenegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balazs","family":"Dome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balazs","family":"Hegedus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,11]]},"reference":[{"issue":"4","key":"1725_CR1","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1378\/chest.126.4.1318","volume":"126","author":"M Pistolesi","year":"2004","unstructured":"Pistolesi M, Rusthoven J (2004) Malignant pleural mesothelioma: update, current management, and newer therapeutic strategies. Chest 126(4):1318\u20131329","journal-title":"Chest"},{"issue":"10026","key":"1725_CR2","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","volume":"387","author":"G Zalcman","year":"2016","unstructured":"Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Riviere F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A, French Cooperative Thoracic I (2016) Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 387(10026):1405\u20131414","journal-title":"Lancet"},{"issue":"10","key":"1725_CR3","doi-asserted-by":"publisher","first-page":"722","DOI":"10.2174\/187152010794728657","volume":"10","author":"KB Dunn","year":"2010","unstructured":"Dunn KB, Heffler M, Golubovskaya V (2010) Evolving therapies and FAK inhibitors for the treatment of cancer. Anti Cancer Agents Med Chem 10(10):722\u2013734","journal-title":"Anti Cancer Agents Med Chem"},{"issue":"10","key":"1725_CR4","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1517\/13543776.2014.948845","volume":"24","author":"E Shanthi","year":"2014","unstructured":"Shanthi E, Krishna MH, Arunesh GM, Venkateswara Reddy K, Sooriya Kumar J, Viswanadhan VN (2014) Focal adhesion kinase inhibitors in the treatment of metastatic cancer: a patent review. Expert Opin Ther Pat 24(10):1077\u20131100","journal-title":"Expert Opin Ther Pat"},{"issue":"5","key":"1725_CR5","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/S0955-0674(99)00021-6","volume":"11","author":"SM Troyanovsky","year":"1999","unstructured":"Troyanovsky SM (1999) Mechanism of cell-cell adhesion complex assembly. Curr Opin Cell Biol 11(5):561\u2013566","journal-title":"Curr Opin Cell Biol"},{"key":"1725_CR6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0074-7696(07)63003-4","volume":"263","author":"VM Golubovskaya","year":"2007","unstructured":"Golubovskaya VM, Cance WG (2007) Focal adhesion kinase and p53 signaling in cancer cells. Int Rev Cytol 263:103\u2013153","journal-title":"Int Rev Cytol"},{"issue":"1","key":"1725_CR7","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/nrm1549","volume":"6","author":"SK Mitra","year":"2005","unstructured":"Mitra SK, Hanson DA, Schlaepfer DD (2005) Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol 6(1):56\u201368","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"1725_CR8","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1158\/0008-5472.CAN-08-3078","volume":"69","author":"M Luo","year":"2009","unstructured":"Luo M, Fan H, Nagy T, Wei H, Wang C, Liu S, Wicha MS, Guan JL (2009) Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem\/progenitor cells. Cancer Res 69(2):466\u2013474","journal-title":"Cancer Res"},{"issue":"8","key":"1725_CR9","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s10585-015-9752-z","volume":"32","author":"I Moen","year":"2015","unstructured":"Moen I, Gebre M, Alonso-Camino V, Chen D, Epstein D, McDonald DM (2015) Anti-metastatic action of FAK inhibitor OXA-11 in combination with VEGFR-2 signaling blockade in pancreatic neuroendocrine tumors. Clin Exp Metastasis 32(8):799\u2013817","journal-title":"Clin Exp Metastasis"},{"issue":"7","key":"1725_CR10","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/nrc1647","volume":"5","author":"GW McLean","year":"2005","unstructured":"McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG, Frame MC (2005) The role of focal-adhesion kinase in cancer - a new therapeutic opportunity. Nat Rev Cancer 5(7):505\u2013515","journal-title":"Nat Rev Cancer"},{"issue":"23","key":"1725_CR11","doi-asserted-by":"publisher","first-page":"7405","DOI":"10.1021\/jm800483v","volume":"51","author":"VM Golubovskaya","year":"2008","unstructured":"Golubovskaya VM, Nyberg C, Zheng M, Kweh F, Magis A, Ostrov D, Cance WG (2008) A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth. J Med Chem 51(23):7405\u20137416","journal-title":"J Med Chem"},{"issue":"6","key":"1725_CR12","first-page":"2417","volume":"6","author":"WG Cance","year":"2000","unstructured":"Cance WG, Harris JE, Iacocca MV, Roche E, Yang X, Chang J, Simkins S, Xu L (2000) Immunohistochemical analyses of focal adhesion kinase expression in benign and malignant human breast and colon tissues: correlation with preinvasive and invasive phenotypes. Clin Cancer Res 6(6):2417\u20132423","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1725_CR13","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1053\/hupa.2003.40","volume":"34","author":"MH Oktay","year":"2003","unstructured":"Oktay MH, Oktay K, Hamele-Bena D, Buyuk A, Koss LG (2003) Focal adhesion kinase as a marker of malignant phenotype in breast and cervical carcinomas. Hum Pathol 34(3):240\u2013245","journal-title":"Hum Pathol"},{"issue":"7","key":"1725_CR14","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1111\/cas.13256","volume":"108","author":"C Hu","year":"2017","unstructured":"Hu C, Chen X, Wen J, Gong L, Liu Z, Wang J, Liang J, Hu F, Zhou Q, Wei L, Shen Y, Zhang W (2017) Antitumor effect of focal adhesion kinase inhibitor PF562271 against human osteosarcoma in vitro and in vivo. Cancer Sci 108(7):1347\u20131356","journal-title":"Cancer Sci"},{"issue":"8","key":"1725_CR15","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/nm.4123","volume":"22","author":"H Jiang","year":"2016","unstructured":"Jiang H, Hegde S, Knolhoff BL, Zhu Y, Herndon JM, Meyer MA, Nywening TM, Hawkins WG, Shapiro IM, Weaver DT, Pachter JA, Wang-Gillam A, DeNardo DG (2016) Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat Med 22(8):851\u2013860","journal-title":"Nat Med"},{"issue":"508","key":"1725_CR16","doi-asserted-by":"publisher","first-page":"eaan8355","DOI":"10.1126\/scisignal.aan8355","volume":"10","author":"B Serrels","year":"2017","unstructured":"Serrels B, McGivern N, Canel M, Byron A, Johnson SC, McSorley HJ, Quinn N, Taggart D, Von Kreigsheim A, Anderton SM, Serrels A, Frame MC (2017) IL-33 and ST2 mediate FAK-dependent antitumor immune evasion through transcriptional networks. Sci Signal 10(508):eaan8355","journal-title":"Sci Signal"},{"key":"1725_CR17","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1080\/15384047.2017.1416937","volume":"0","author":"R Kanteti","year":"2018","unstructured":"Kanteti R, Mirzapoiazova T, Riehm JJ, Dhanasingh I, Mambetsariev B, Wang J, Kulkarni P, Kaushik G, Seshacharyulu P, Ponnusamy MP, Kindler HL, Nasser MW, Batra SK, Salgia R (2018) Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma. Cancer Biol Ther 0:316\u2013327","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"1725_CR18","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ygyno.2014.04.044","volume":"134","author":"NR Shah","year":"2014","unstructured":"Shah NR, Tancioni I, Ward KK, Lawson C, Chen XL, Jean C, Sulzmaier FJ, Uryu S, Miller NL, Connolly DC, Schlaepfer DD (2014) Analyses of merlin\/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer. Gynecol Oncol 134(1):104\u2013111","journal-title":"Gynecol Oncol"},{"issue":"237","key":"1725_CR19","doi-asserted-by":"publisher","first-page":"237ra268","DOI":"10.1126\/scitranslmed.3008639","volume":"6","author":"IM Shapiro","year":"2014","unstructured":"Shapiro IM, Kolev VN, Vidal CM, Kadariya Y, Ring JE, Wright Q, Weaver DT, Menges C, Padval M, McClatchey AI, Xu Q, Testa JR, Pachter JA (2014) Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship. Sci Transl Med 6(237):237ra268","journal-title":"Sci Transl Med"},{"issue":"24","key":"1725_CR20","doi-asserted-by":"publisher","first-page":"10854","DOI":"10.1073\/pnas.92.24.10854","volume":"92","author":"AB Bianchi","year":"1995","unstructured":"Bianchi AB, Mitsunaga SI, Cheng JQ, Klein WM, Jhanwar SC, Seizinger B, Kley N, Klein-Szanto AJ, Testa JR (1995) High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci U S A 92(24):10854\u201310858","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"44","key":"1725_CR21","doi-asserted-by":"publisher","first-page":"5960","DOI":"10.1038\/sj.onc.1209587","volume":"25","author":"PI Poulikakos","year":"2006","unstructured":"Poulikakos PI, Xiao GH, Gallagher R, Jablonski S, Jhanwar SC, Testa JR (2006) Re-expression of the tumor suppressor NF2\/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK. Oncogene 25(44):5960\u20135968","journal-title":"Oncogene"},{"issue":"3","key":"1725_CR22","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/embor.2012.11","volume":"13","author":"W Li","year":"2012","unstructured":"Li W, Cooper J, Karajannis MA, Giancotti FG (2012) Merlin: a tumour suppressor with functions at the cell cortex and in the nucleus. EMBO Rep 13(3):204\u2013215","journal-title":"EMBO Rep"},{"issue":"12","key":"1725_CR23","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1093\/annonc\/mdw427","volume":"27","author":"JC Soria","year":"2016","unstructured":"Soria JC, Gan HK, Blagden SP, Plummer R, Arkenau HT, Ranson M, Evans TR, Zalcman G, Bahleda R, Hollebecque A, Lemech C, Dean E, Brown J, Gibson D, Peddareddigari V, Murray S, Nebot N, Mazumdar J, Swartz L, Auger KR, Fleming RA, Singh R, Millward M (2016) A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors. Ann Oncol 27(12):2268\u20132274","journal-title":"Ann Oncol"},{"issue":"5","key":"1725_CR24","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s00280-016-3010-1","volume":"77","author":"T Shimizu","year":"2016","unstructured":"Shimizu T, Fukuoka K, Takeda M, Iwasa T, Yoshida T, Horobin J, Keegan M, Vaickus L, Chavan A, Padval M, Nakagawa K (2016) A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 77(5):997\u20131003","journal-title":"Cancer Chemother Pharmacol"},{"key":"1725_CR25","doi-asserted-by":"publisher","first-page":"5522","DOI":"10.1038\/onc.2017.147","volume":"36","author":"T Kato","year":"2017","unstructured":"Kato T, Sato T, Yokoi K, Sekido Y (2017) E-cadherin expression is correlated with focal adhesion kinase inhibitor resistance in Merlin-negative malignant mesothelioma cells. Oncogene 36:5522\u20135531","journal-title":"Oncogene"},{"issue":"11 Supplement","key":"1725_CR26","doi-asserted-by":"crossref","first-page":"A249","DOI":"10.1158\/1535-7163.TARG-11-A249","volume":"10","author":"UA Hirt","year":"2011","unstructured":"Hirt UA, Braunger J, Schleicher M, Weyer-Czernilofsky U, Garin-Chesa P, Bister B, Stadtmueller H, Sapountzis I, Kraut N, Adolf GR (2011) Abstract A249: BI 853520, a potent and highly selective inhibitor of protein tyrosine kinase 2 (focal adhesion kinase), shows efficacy in multiple xenograft models of human cancer. Mol Cancer Ther 10(11 Supplement):A249\u2013A249","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"1725_CR27","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41389-018-0032-z","volume":"7","author":"UA Hirt","year":"2018","unstructured":"Hirt UA, Waizenegger IC, Schweifer N, Haslinger C, Gerlach D, Braunger J, Weyer-Czernilofsky U, Stadtmuller H, Sapountzis I, Bader G, Zoephel A, Bister B, Baum A, Quant J, Kraut N, Garin-Chesa P, Adolf GR (2018) Efficacy of the highly selective focal adhesion kinase inhibitor BI 853520 in adenocarcinoma xenograft models is linked to a mesenchymal tumor phenotype. Oncogenesis 7(2):21","journal-title":"Oncogenesis"},{"issue":"20","key":"1725_CR28","doi-asserted-by":"publisher","first-page":"3094","DOI":"10.1016\/j.yexcr.2013.08.018","volume":"319","author":"T Garay","year":"2013","unstructured":"Garay T, Juhasz E, Molnar E, Eisenbauer M, Czirok A, Dekan B, Laszlo V, Hoda MA, Dome B, Timar J, Klepetko W, Berger W, Hegedus B (2013) Cell migration or cytokinesis and proliferation?--revisiting the \u201cgo or grow\u201d hypothesis in cancer cells in vitro. Exp Cell Res 319(20):3094\u20133103","journal-title":"Exp Cell Res"},{"key":"1725_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzym Regul 22:27\u201355","journal-title":"Adv Enzym Regul"},{"issue":"2","key":"1725_CR30","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/path.4567","volume":"237","author":"V Laszlo","year":"2015","unstructured":"Laszlo V, Hoda MA, Garay T, Pirker C, Ghanim B, Klikovits T, Dong YW, Rozsas A, Kenessey I, Szirtes I, Grusch M, Jakopovic M, Samarzija M, Brcic L, Kern I, Rozman A, Popper H, Zochbauer-Muller S, Heller G, Altenberger C, Ziegler B, Klepetko W, Berger W, Dome B, Hegedus B (2015) Epigenetic down-regulation of integrin alpha7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma. J Pathol 237(2):203\u2013214","journal-title":"J Pathol"},{"issue":"1\u20132","key":"1725_CR31","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1023\/B:NEON.0000021826.73020.f3","volume":"67","author":"B Hegedus","year":"2004","unstructured":"Hegedus B, Zach J, Czirok A, Lovey J, Vicsek T (2004) Irradiation and Taxol treatment result in non-monotonous, dose-dependent changes in the motility of glioblastoma cells. J Neuro-Oncol 67(1\u20132):147\u2013157","journal-title":"J Neuro-Oncol"},{"issue":"6","key":"1725_CR32","doi-asserted-by":"publisher","first-page":"e1000412","DOI":"10.1371\/journal.pbio.1000412","volume":"8","author":"C Kilkenny","year":"2010","unstructured":"Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG (2010) Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 8(6):e1000412","journal-title":"PLoS Biol"},{"issue":"5","key":"1725_CR33","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/bjc.2015.9","volume":"112","author":"B Ghanim","year":"2015","unstructured":"Ghanim B, Klikovits T, Hoda MA, Lang G, Szirtes I, Setinek U, Rozsas A, Renyi-Vamos F, Laszlo V, Grusch M, Filipits M, Scheed A, Jakopovic M, Samarzija M, Brcic L, Stancic-Rokotov D, Kern I, Rozman A, Dekan G, Klepetko W, Berger W, Glasz T, Dome B, Hegedus B (2015) Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study. Br J Cancer 112(5):783\u2013792","journal-title":"Br J Cancer"},{"issue":"4","key":"1725_CR34","doi-asserted-by":"publisher","first-page":"R56","DOI":"10.1186\/bcr2615","volume":"12","author":"VJ Tuominen","year":"2010","unstructured":"Tuominen VJ, Ruotoistenmaki S, Viitanen A, Jumppanen M, Isola J (2010) ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast Cancer Res : BCR 12(4):R56","journal-title":"Breast Cancer Res : BCR"},{"key":"1725_CR35","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.pharmthera.2014.10.001","volume":"146","author":"BY Lee","year":"2015","unstructured":"Lee BY, Timpson P, Horvath LG, Daly RJ (2015) FAK signaling in human cancer as a target for therapeutics. Pharmacol Ther 146:132\u2013149","journal-title":"Pharmacol Ther"},{"issue":"10","key":"1725_CR36","doi-asserted-by":"publisher","first-page":"764","DOI":"10.4161\/cbt.9.10.11434","volume":"9","author":"I Tanjoni","year":"2010","unstructured":"Tanjoni I, Walsh C, Uryu S, Tomar A, Nam JO, Mielgo A, Lim ST, Liang C, Koenig M, Sun C, Patel N, Kwok C, McMahon G, Stupack DG, Schlaepfer DD (2010) PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments. Cancer Biol Ther 9(10):764\u2013777","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"1725_CR37","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jbiotec.2010.01.012","volume":"148","author":"F Hirschhaeuser","year":"2010","unstructured":"Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser W, Kunz-Schughart LA (2010) Multicellular tumor spheroids: an underestimated tool is catching up again. J Biotechnol 148(1):3\u201315","journal-title":"J Biotechnol"},{"key":"1725_CR38","doi-asserted-by":"publisher","unstructured":"Langhans SA (2018) Three-dimensional in vitro cell culture models in drug discovery and drug repositioning. Front Pharmacol 9(6). https:\/\/doi.org\/10.3389\/fphar.2018.00006","DOI":"10.3389\/fphar.2018.00006"},{"issue":"8","key":"1725_CR39","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1038\/cdd.2009.32","volume":"16","author":"J Daubriac","year":"2009","unstructured":"Daubriac J, Fleury-Feith J, Kheuang L, Galipon J, Saint-Albin A, Renier A, Giovannini M, Galateau-Salle F, Jaurand MC (2009) Malignant pleural mesothelioma cells resist anoikis as quiescent pluricellular aggregates. Cell Death Differ 16(8):1146\u20131155","journal-title":"Cell Death Differ"},{"issue":"4","key":"1725_CR40","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.stemcr.2017.02.005","volume":"8","author":"W Blum","year":"2017","unstructured":"Blum W, Pecze L, Felley-Bosco E, Wu L, de Perrot M, Schwaller B (2017) Stem cell factor-based identification and functional properties of in vitro-selected subpopulations of malignant mesothelioma cells. Stem Cell Reports 8(4):1005\u20131017","journal-title":"Stem Cell Reports"},{"issue":"5","key":"1725_CR41","doi-asserted-by":"publisher","first-page":"e0119549","DOI":"10.1371\/journal.pone.0119549","volume":"10","author":"EA Pasdar","year":"2015","unstructured":"Pasdar EA, Smits M, Stapelberg M, Bajzikova M, Stantic M, Goodwin J, Yan B, Stursa J, Kovarova J, Sachaphibulkij K, Bezawork-Geleta A, Sobol M, Filimonenko A, Tomasetti M, Zobalova R, Hozak P, Dong LF, Neuzil J (2015) Characterisation of mesothelioma-initiating cells and their susceptibility to anti-cancer agents. PLoS One 10(5):e0119549","journal-title":"PLoS One"},{"key":"1725_CR42","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.2147\/OTT.S122463","volume":"10","author":"DB Kong","year":"2017","unstructured":"Kong DB, Chen F, Sima N (2017) Focal adhesion kinases crucially regulate TGFbeta-induced migration and invasion of bladder cancer cells via Src kinase and E-cadherin. OncoTargets Ther 10:1783\u20131792","journal-title":"OncoTargets Ther"},{"issue":"11","key":"1725_CR43","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1097\/JTO.0b013e3182a59f45","volume":"8","author":"G Ali","year":"2013","unstructured":"Ali G, Borrelli N, Riccardo G, Proietti A, Pelliccioni S, Niccoli C, Boldrini L, Lucchi M, Mussi A, Fontanini G (2013) Differential expression of extracellular matrix constituents and cell adhesion molecules between malignant pleural mesothelioma and mesothelial hyperplasia. J Thorac Oncol 8(11):1389\u20131395","journal-title":"J Thorac Oncol"},{"issue":"15","key":"1725_CR44","doi-asserted-by":"publisher","first-page":"3718","DOI":"10.1158\/1078-0432.CCR-14-2021","volume":"22","author":"M Roy-Luzarraga","year":"2016","unstructured":"Roy-Luzarraga M, Hodivala-Dilke K (2016) Molecular pathways: endothelial cell FAK-A target for cancer treatment. Clin Cancer Res 22(15):3718\u20133724","journal-title":"Clin Cancer Res"},{"key":"1725_CR45","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.2217\/fon-2017-0307","volume":"13","author":"S Brosseau","year":"2017","unstructured":"Brosseau S, Assoun S, Naltet C, Steinmetz C, Gounant V, Zalcman G (2017) A review of bevacizumab in the treatment of malignant pleural mesothelioma. Future Oncol 13:2537\u20132546","journal-title":"Future Oncol"},{"issue":"5","key":"1725_CR46","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1172\/JCI85086","volume":"126","author":"M Haemmerle","year":"2016","unstructured":"Haemmerle M, Bottsford-Miller J, Pradeep S, Taylor ML, Choi HJ, Hansen JM, Dalton HJ, Stone RL, Cho MS, Nick AM, Nagaraja AS, Gutschner T, Gharpure KM, Mangala LS, Rupaimoole R, Han HD, Zand B, Armaiz-Pena GN, Wu SY, Pecot CV, Burns AR, Lopez-Berestein G, Afshar-Kharghan V, Sood AK (2016) FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. J Clin Invest 126(5):1885\u20131896","journal-title":"J Clin Invest"},{"issue":"19","key":"1725_CR47","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1093\/jnci\/djt210","volume":"105","author":"Y Kang","year":"2013","unstructured":"Kang Y, Hu W, Ivan C, Dalton HJ, Miyake T, Pecot CV, Zand B, Liu T, Huang J, Jennings NB, Rupaimoole R, Taylor M, Pradeep S, Wu SY, Lu C, Wen Y, Huang J, Liu J, Sood AK (2013) Role of focal adhesion kinase in regulating YB\u20131\u2013mediated paclitaxel resistance in ovarian cancer. JNCI: J Natl Cancer Instit 105(19):1485\u20131495","journal-title":"JNCI: J Natl Cancer Instit"},{"issue":"7","key":"1725_CR48","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1164\/rccm.201404-0658OC","volume":"190","author":"K Schelch","year":"2014","unstructured":"Schelch K, Hoda MA, Klikovits T, Munzker J, Ghanim B, Wagner C, Garay T, Laszlo V, Setinek U, Dome B, Filipits M, Pirker C, Heffeter P, Selzer E, Tovari J, Torok S, Kenessey I, Holzmann K, Grasl-Kraupp B, Marian B, Klepetko W, Berger W, Hegedus B, Grusch M (2014) Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy. Am J Respir Crit Care Med 190(7):763\u2013772","journal-title":"Am J Respir Crit Care Med"},{"issue":"1\u20132","key":"1725_CR49","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.canlet.2014.03.007","volume":"348","author":"P Dao","year":"2014","unstructured":"Dao P, Jarray R, Smith N, Lepelletier Y, Le Coq J, Lietha D, Hadj-Slimane R, Herbeuval JP, Garbay C, Raynaud F, Chen H (2014) Inhibition of both focal adhesion kinase and fibroblast growth factor receptor 2 pathways induces anti-tumor and anti-angiogenic activities. Cancer Lett 348(1\u20132):88\u201399","journal-title":"Cancer Lett"}],"container-title":["Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00109-018-1725-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-018-1725-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-018-1725-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T00:59:22Z","timestamp":1662598762000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00109-018-1725-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,11]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["1725"],"URL":"https:\/\/doi.org\/10.1007\/s00109-018-1725-7","relation":{},"ISSN":["0946-2716","1432-1440"],"issn-type":[{"value":"0946-2716","type":"print"},{"value":"1432-1440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,11]]},"assertion":[{"value":"12 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"As stated in the manuscript: All mentioned animal experiments were performed according to the ARRIVE guidelines [] and to the animal welfare regulations of the host institute (permission number: PEI\/001\/2574-6\/2015).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Irene Waizenegger is an employee of Boehringer Ingelheim RCV GmbH & CoKG. The other authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}